Aventa Genomics, a joint venture of Arima Genomics and Protean BioDiagnostics, launched the Aventa FusionPlus test for patients with solid cancers.
Profluent successfully edits human genome with OpenCRISPR-1, the world’s first AI-created and open-source gene editor
Learn more about how prostate cancer is detected, risk factors, and treatments on our full video. Watch the full video on prostate cancer by clicking…
Trilliant Health, the healthcare industry’s leading analytics and market research firm, today announced the release of the entry-level tier of its Pro
Q Bio Inc., an innovator in medical imaging technology, today announced the launch of Tensor Field Mapping (TFM), a new technology for Magnetic Resona
Breaking, a plastic degradation and synthetic biology company, gestated at Colossal Biosciences based on a core discovery out of the Wyss Institute fo
TELUS International (NYSE and TSX: TIXT), a leading digital customer experience (CX) innovator that designs, builds, and delivers next-generation solu
Following to the previous information on March 11th, 2024, we are excited to share our latest development status. We are pleased to announce the proto
CerebraAI is developing its GenAI algorithm to predict personalized “norms” in brain imaging based on NCCT scans for acute ischemic stroke detection.
Aventa Genomics has launched its next-generation sequencing (NGS) test, Aventa FusionPlus, to identify gene fusions and translocations.
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FD
